New apalutamide study opens for prostate cancer

February 14, 2018

A new phase 3 study at Providence Cancer Institute will compare the effectiveness of three different treatment regimens in men with biochemically recurrent prostate cancer:

Experimental arm: apalutamide, an investigational, next-generation oral androgen receptor (AR) inhibitor, plus degarelix, a hormonal therapy used to reduce testosterone
Experimental arm: apalutamide and degarelix plus abiraterone acetate and prednisone
Control arm: degarelix alone

“Apalutamide (ARN-509) reduced the risk of metastasis or death by 72% in patients with nonmetastatic castration-resistant prostate cancer,” according to findings from the phase 3 SPARTAN trial reported in OncLive on Feb. 5. The SPARTAN trial, published in the New England Journal of Medicine on Feb. 8, found that “median metastasis-free survival was more than 2 years longer” for men who received apalutamide. Read more in the New York Times.

Brendan Curti, M.D., the principal investigator of the new three-arm study at Providence Cancer Institute, is a medical oncologist and director of genitourinary oncology research at the Earle A. Chiles Research Institute.

See Providence study details here:

A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer

More prostate cancer studies

This study is one of three clinical trials open to men with prostate cancer at Providence Cancer Institute. See all prostate cancer studies.

To refer patients to any of these studies, call Providence Cancer Institute’s Clinical Research office at 503-215-2614 or visit oregon.providence.org/clinical-trials.

Welcome to your journey for creating a healthier you

New apalutamide study opens for prostate cancer

See Providence study details here:

More prostate cancer studies

Previous Article

Next Article

New apalutamide study opens for prostate cancer

See Providence study details here:

More prostate cancer studies

Previous Article

Next Article

Most Recent Articles

Learn why a proposed FSED is not right for our community.

New study evaluates a type of CAR T-cell therapy called liso-cel. Researchers will collect data from multiple groups in a study that may give patients hope for long-term remission and quality of life.

Explore promising clinical trials at Providence Cancer Institute that are investigating immunotherapy for early-stage TNBC and high-risk, HR-positive breast cancer.

Providence Alaska Medical Center recently launched a new care model designed to enhance patient safety and help address the nationwide nurse shortage.

Using a new minimally invasive procedure, Dr. Rishi Kaushal saved Candy Lugo’s life by quickly removing a blood clot that was preventing her from breathing normally.

Over the last ten years, the center has been committed to providing children and adults with a secure and clean environment to play, learn and connect with neighbors and improve their health.

Providence Saint Joseph Medical Center has named Cindy Mahal, DNP, MS, RN, CNOR, its Chief Administrative Officer.

This milestone is yet another example of the exceptional standards we uphold across our ministries and in Orange County said Brian Helleland, chief executive of Providence Orange County/High Desert.

Throughout Breast Cancer Awareness Month, women are urged to prioritize exams, healthy living and follow-ups.

Providence Cancer Institute in partnership with AIM at Melanoma present a free online event designed to educate and empower patients and care partners affected by melanoma.

Providence Holy Cross Medical Center is committed to the health and wellness of the community and will make reasonable efforts to ensure that the community is informed of this service line closure.

Debbie Deccio celebrates 50 years of employment at Providence St. Mary

CA Attorney General Lawsuit

Providence Holy Cross Medical Center is dedicated to providing the best possible outcomes for every patient at every stage of a pancreatic cancer diagnosis.

How leading-edge surgery and a strong spirit helped one woman overcome pancreatic cancer.

A new study approach reflects a deeper understanding of cancer at the molecular level and marks a shift away from one-size-fits-all treatments.

For decades, thermal energy—both heat and cold—has been used to treat atrial fibrillation (afib). A breakthrough ablation technology uses a new type of energy—pulsed electric fields—to offer patients